Dose: 0.1 to 0.12 mg/kg
Single Dose: 0.11 (0.11)
Frequency: 8 hourly
Route: Inhalation
Instructions: twice a day.

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

. It is of Semi Synthetic origin and belongs to Glycyrrhetinic Acid. It belongs to Anti-ulcer (GI) pharmacological group on the basis of mechanism of action and also classified in Antacids and Antipeptic Ulcerant pharmacological group.The Molecular Weight of Carbenoxolone (Na) is 614.70. It is weakly acidic drug, 4.40% solution of the drug is isotonic and Its pKa is 6.7, 7.1.

Carbenoxolone (Na) is contraindicated in conditions like Hypertension,Cardiac failure,Hypokalaemia,Renal diseases,Hepatic disease.

The severe or irreversible adverse effects of Carbenoxolone (Na), which give rise to further complications include Hypokalemia, Fluid retension, Increased blood pressure.Carbenoxolone (Na) produces potentially life-threatening effects which include Hypokalemia, Hypertension, Cardiac failure, Papilloedema. which are responsible for the discontinuation of Carbenoxolone (Na) therapy.The signs and symptoms that are produced after the acute overdosage of Carbenoxolone (Na) include Hypokalemia.The symptomatic adverse reactions produced by Carbenoxolone (Na) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Weight gain, Increased weight.

Carbenoxolone (Na) is primarily indicated in conditions like Aphthous mouth ulceration, Benign gastric ulcer, Duodenal ulcer, Peptic oesophagitis.

Carbenoxolone (Na) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAluminium Hydroxide and OxideAmiloride (HCl)Amiloride (HCl)BendrofluazideCanrenoate (K)ChlorothiazideChlorthalidoneClopamideDeflazacortDiazoxideHypotensive effect of diazoxide antagonised by Carbenoxolone.DigitoxinDigoxinHydrochlorothiazideLactitol MonohydrateLofexidineTheoretical potential for CARBENOXOLONE reducing the HYPOTENSIVE effect of LOFEXIDINE HYDROCHLORIDE. ModerateMetyrosineTheoretical potential for CARBENOXOLONE reducing the HYPOTENSIVE effect of METIROSINE. ModeratePerindoprilTheoretical potential for CARBENOXOLONE reducing the HYPOTENSIVE effect of Perindopril Erbumine. ModeratePiretanidePotassium CanrenoateSpironolactone These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store Below 40°C.

Avoid carbenoxolone in patients with hypokalaemia, in elderly patients, in children. It should be used with caution in patients with cardiac disease, hypertension or impaired kidney or liver function. Avoid use during pregnancy.